| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| A1040-100 | Anti-human FOLR1 antibody | 100µg | $185 | Order |
| A1040-200 | Anti-human FOLR1 antibody | 200µg | $325 | Order |
| Catalog Number | A1040 |
|---|---|
| Product Name | Anti-human FOLR1 antibody |
| Source | Recombinant anti-human FOLR1mAb produced from HEK293 cells |
| Clone | Mirvetuximab(VH and VL sequences are derived from Olga AB, et. al. US Patent # 2024/1032584 A1) |
| Species Reactivity | Human |
| Isotype | Human IgG1 |
| Purity | >95% |
| Formulation | 1xPBS, pH6.8. Sterile |
| Stability & Storage | 1 month at 4oC; 12 months at <-20oC; Avoid repeated freeze-thaw |
| Protein Aggregation | Not obvious on SDS-PAGE |
| Application | Flow cytometry, ELISA, cell-based assay |
| Product Datasheet: | Download PDF |
Detection of human FOLR1 expression on Human FOLR1-CHO-K1 cells (Cat. #C3038) by flow cytometry. Anti-human FOLR1 antibody Mirvetuximab (Cat. #A1040) was incubated with human FOLR1-CHO-K1 cells(Cat. #C3038), followed by staining with PE-anti-human IgG.
Folate receptor 1 (Folate receptor alpha, FOLR1) is a glycosyl-phosphatidylinositol (GPI)-linked membrane-bound protein, which exhibits a high affinity for folic acid and its reduced folic acid derivatives. FOLR1 mediates delivery of 5-methyltetrahydrofolate to the interior of cells. FOLR1 is involved in several cellular processes, including cell growth, survival, and signaling pathways. FOLR1 is expressed in kidney, placenta, serum, milk, and in several cell lines, while its expression has been found to be elevated in tumors of epithelial origin compared to normal tissue, including ovarian, breast, brain, lung and colorectal cancers. The tumor specificity of FOLR1 makes it a promising therapeutic target for the treatment of cancer.
Zheng Y and Cantley LC. J Exp Med 216, 253–266. 2019.
Scaranti M, Cojocaru E, Banerjee S, Banerji U. Nature Reviews. Clinical Oncology. 17: 349–359.2020.
Shen J, Hu Y, Putt KS, Singhal S, Han H, Visscher DW, Murphy LM, Low PS. Oncotarget. 15:4485-4495. 2017.
Nawaz FZ, Kipreos ET. Trends Endocrinol Metab. Mar. 33:159-174. 2022.
Antony AC. Annu Rev Nutr. 16:501-21. 1996.